The world's first vaccine against dengue, developed by French drugmaker Sanofi, has shown the ability to protect against disease caused by three of four dengue virus strains in a keenly awaited clinical trial in Thailand.
Sanofi said on Wednesday the proof of efficacy was "a key milestone" in the 70-year quest to develop a viable dengue shot, adding the results also confirmed the safety profile of the vaccine candidate.
The mosquito-borne disease - also known as "breakbone fever" - is a threat to nearly 3 billion people and is caused by four different types of virus, none of which confers immunity from the others.
Sanofi's vaccine generated an antibody response for all four dengue virus types, but evidence of protection was only demonstrated against three of the four circulating in Thailand. Sanofi said researchers were carrying out analyses to understand the lack of protection for the fourth serotype.
The company's vaccine unit, Sanofi Pasteur, has already invested 350 million euros ($423 million) in a new French factory to make the three-dose vaccine and believes its product could generate 1 billion euros in yearly sales.
But uptake of the vaccine will depend on precisely how well doctors believe it can protect populations at risk in fast-expanding tropical cities from Rio to Manila, as well as travelers.
Sanofi gave no details on the level of protection in a brief statement. The full data are now being reviewed by scientific experts and public health officials, with detailed results to be published later this year.
Sanofi previously said it planned to present the findings at the annual meeting of the American Society of Tropical Medicine and Hygiene in Atlanta in November.
Large-scale late-stage Phase III clinical studies with 31,000 participants are under way with Sanofi's vaccine in 10 countries in Asia and Latin America.
H5N1 bird flu spreads to totally 11 states in Nigeria.
Since BSE was first identified in Britain in 1986, strict controls have tempered the spread of the disease.
The fatality brings the total death count to 84 in Egypt since the virus first appeared in 2006.
Precision medicine has been propelled by advances in two areas in particular: cancer and pharmacogenomics, the study of how DNA interacts with drug
The bacterial disease is mainly spread from one rodent to another by fleas.
Ebola has been "a mega crisis and it overwhelmed the capacity of WHO".
Pauline Cafferkey was admitted to the Royal Free Hospital after falling ill on her return from Sierra Leone, where she had been working for the charity Save the Children
"Both for malaria and AIDS we're seeing that the tools that will let us do 95 to 100 percent reduction, those tools will be invented during this 15-year period", said Gates.
A five-year-old boy died from the virus in the southern Assiut province
"The probability of global catastrophe is very high," says advocacy group
Nigeria H5N1 bird flu now in 7 states, suspected in 140,000 birds
Using video feedback-based therapy to help parents understand and respond to their baby's early communication style might help modify emerging autism symptoms
The unprecedented outbreak has so far killed more than 8,400 people, overwhelmingly in Liberia, Guinea and Sierra Leone.
Obama launched a new precision medicine initiative to bring closer to curing diseases like cancer and diabetes